##plugins.themes.bootstrap3.article.main##

Neuromyelitis Optica spectrum disorder (NMOSD), also known as Devic disease, is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and inflammation of the spinal cord (myelitis). We present the case of a 25-year-old female patient who presented with complaints of lower back ache, decreased vision and double vision, generalized body pain, neck pain and vomiting. On examination, Extraocular Movement (EOM) showed right gaze restriction with nystagmus; her serum Neuromyelitis Optica (NMO) result was positive; and her MRI showed lesions in the brain. Insight of her presenting illness and investigations, she was successfully treated with IV steroids, plasmapheresis, and immunosuppressive therapy and was neurologically stable. We present this rare case to clinically enlighten the diagnosis and treatment of NMOSD.

References

  1. Neuromyelitis optica spectrum disorder - NORD (national organization for Rare disorders) [Internet]. NORD (National Organization for Rare Disorders). 2015 [cited 2022 Jun 22]. Available from: https://rarediseases.org/rare-diseases/neuromyelitis-optica/.
     Google Scholar
  2. Hor JY, Asgari N, Nakashima I, Broadley SA, Leite MI, Kissani N, et al. Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide. Front Neurol. 2020; 11: 501.
     Google Scholar
  3. Das D, Bhattacharjee H, Rehman O, Deori N, Magdalene D, Bharali G, et al. Neuromyelitis optica spectrum disorder post-COVID-19 infection: A rare case report from Northeast India. Indian Journal of Ophthalmology. 2002; 70(5): 1833–1836.
     Google Scholar
  4. Beiruti K, Saleh SA, Daitzchman M, Shahien R. Neuromyelitis Optica Spectrum Disorder: A Case Report. Journal of Multiple Sclerosis. 2016; 3(4).
     Google Scholar
  5. Tambunan L, Ritarwan K, Surbakti KP. Neuromyelitis optica spectrum disorder: A case report of effective combination immunosuppressant, corticosteroids, and therapeutic plasma exchange. Open Access Macedonian Journal of Medical Sciences. 2019; 7(20): 3433–3436.
     Google Scholar
  6. Yaregal S, Bekele N, Gebrewold Y, Tadesse A. Neuromyelitis optica spectrum disorder: A case report. Int Med Case Rep J. 2021; 14: 643–648.
     Google Scholar
  7. Huda S, Whittam D, Bhojak M, Chamberlain J, Noonan C, Jacob A. Neuromyelitis optica spectrum disorders. Clinical Medicine (London, England). 2019; 19(2): 169–176.
     Google Scholar
  8. Kessler RA, Mealy MA, Levy M. Treatment of neuromyelitis optica spectrum disorder: Acute, preventive, and symptomatic. Current Treatment Options in Neurology. 2016; 18(1): 2.
     Google Scholar
  9. Klawiter EC, Alvarez E, Xu J, Paciorkowski AR, Zhu L, Parks BJ, et al. NMO-IgG detected in CSF in seronegative neuromyelitis optica. Neurology. 2009; 72(12): 1101–1103.
     Google Scholar